Mary Caffrey

Johnetta Blakely, MD, MS, MMHC, discusses her new role as chief medical officer of the Community Oncology Alliance during an interview that will appear in the June issue of Evidence-Based Oncology.

Analyses to be presented at ASCO show zanubrutinib offers improved survival benefits and longer time to the next treatment over another BTK inhibitor in 2 common indications.

ASCO highlights MorningSun: subcutaneous mosunetuzumab offers a chemotherapy-free option for elderly patients with DLBCL, improving quality of life beyond R-CHOP.

An Institute for Value-Based Medicine® event in Princeton highlights how the state's leading cancer care providers meet the needs of a diverse population.

ASCO 2026 spotlights practice-changing cancer data: PROTEUS in prostate cancer, RAS(ON) inhibitor daraxonrasib, new bispecifics, and GLP-1 signals.

Mezigdomide, a powerful CELMoD, doubles PFS in relapsed multiple myeloma, offering hope when IMiDs stop working.

Teclistamab bispecific from Johnson & Johnson boosts early-line multiple myeloma outcomes, fueling safer outpatient therapy options.

Early data for LINKER-AL2 shows Regeneron’s linvoseltamab drives rapid and deep responses in patients who have relapsed after frontline treatment for AL amyloidosis, a condition for which there are no approved therapies.

Data confirm the use of daratumumab, bortezomib, lenalidomide, and dexamethasone as the standard of care in newly diagnosed multiple myeloma.

Data presented at ASCO support wider use of prophylactic therapy to prevent cytokine release syndrome as efforts expand to promote bispecifics in treatment of multiple myeloma.